FDA Proposes Rule to Eliminate Adequate Provision Requirement for Prescription Drug Television Ads

The Food and Drug Administration (FDA) is preparing a proposed rule that would eliminate the “adequate provision” requirement for direct-to-consumer (DTC) television advertisements for prescription drugs. This regulatory change would effectively prohibit the broadcast of such advertisements by removing the mechanism that currently allows manufacturers to air them while providing alternative access to full product labeling.

Under current federal regulations, pharmaceutical companies may broadcast television advertisements for prescription drugs if they include a “major statement” of side effects and make “adequate provision” for viewers to access the full FDA-approved product labeling. This provision typically involves directing consumers to a website, a toll-free telephone number, a print advertisement, or a healthcare professional. By removing this requirement, the proposed rule would eliminate the legal pathway that permits these television spots to air. The agency’s forthcoming proposal follows ongoing discussions regarding the impact of broadcast advertising on patient-provider interactions and the accessibility of complex medical information in short-form media.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: July 7, 2026

Author

GOAI